Leflunomide Aspire Pharma (Malta) (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for making pyrimidine nucleotides. This limits the replication of activated lymphocytes, decreasing the autoimmune activity that drives joint inflammation in rheumatoid and psoriatic arthritis.

The exact dose of leflunomide is determined by the prescribing physician based on the patient’s clinical condition, renal and hepatic function, and other individual factors. Dosage adjustments are made according to therapeutic response and safety monitoring.

Leflunomide is classified as pregnancy category X because it can cause fetal malformations and embryotoxicity. It is contraindicated in pregnancy and women of child‑bearing potential must use effective contraception. Breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Leflunomide is an oral synthetic DMARD that differs from biologic agents such as TNF‑α inhibitors. It offers the convenience of once‑daily dosing and does not require injection, but it carries a distinct safety profile, especially regarding liver toxicity and teratogenicity, which must be weighed against efficacy.

Leflunomide tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Leflunomide is taken orally, usually as a tablet swallowed whole with water. The medication may be taken with or without food, but patients should follow the specific instructions provided by their healthcare professional.

The most serious risks include severe liver injury, life‑threatening skin reactions such as Stevens‑Johnson syndrome, bone‑marrow suppression leading to anemia or neutropenia, and pulmonary toxicity. Prompt medical attention is required if any of these symptoms arise.

Leflunomide should not be used by pregnant women, women planning pregnancy, or those who are not using reliable contraception. It is also contraindicated in patients with severe liver disease, uncontrolled hypertension, or known hypersensitivity to the drug.